Morgan Stanley
HOWL icon

Morgan Stanley’s Werewolf Therapeutics HOWL Stock Holding History

Morgan Stanley’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.88K Sell
19,108
-14,691
-43% -$8.95K ﹤0.01% 7143
2026
Q1 		$28.1K Sell
33,799
-12,203
-27% -$8.36K ﹤0.01% 6612
2025
Q4 		$29.1K Buy
46,002
+26,750
+139% +$32.5K ﹤0.01% 6583
2025
Q3 		$37.9K Sell
19,252
-7,948
-29% -$10.9K ﹤0.01% 6495
2025
Q2 		$29.6K Sell
27,200
-80,627
-75% -$83K ﹤0.01% 6517
2025
Q1 		$105K Sell
107,827
-30,315
-22% -$39.7K ﹤0.01% 5988
2024
Q4 		$204K Buy
138,142
+19,102
+16% +$38.9K ﹤0.01% 5776
2024
Q3 		$252K Buy
119,040
+70,028
+143% +$159K ﹤0.01% 5663
2024
Q2 		$120K Buy
49,012
+28,433
+138% +$137K ﹤0.01% 5901
2024
Q1 		$133K Buy
20,579
+19,979
+3,330% +$116K ﹤0.01% 5876
2023
Q4 		$2.32K Sell
600
-1,900
-76% -$4.85K ﹤0.01% 7019
2023
Q3 		$5.35K Hold
2,500
– – ﹤0.01% 6901
2023
Q2 		$7.63K Hold
2,500
– – ﹤0.01% 6897
2023
Q1 		$6.5K Sell
2,500
-12
-0.5% -$36 ﹤0.01% 7000
2022
Q4 		$5.15K Sell
2,512
-7,975
-76% -$20.9K ﹤0.01% 7138
2022
Q3 		$47K Sell
10,487
-11,799
-53% -$64.1K ﹤0.01% 6436
2022
Q2 		$91K Buy
22,286
+14,656
+192% +$66.9K ﹤0.01% 6324
2022
Q1 		$33K Sell
7,630
-433
-5% -$3.03K ﹤0.01% 6899
2021
Q4 		$96K Buy
8,063
+6,549
+433% +$98.8K ﹤0.01% 6466
2021
Q3 		$26K Buy
1,514
+1,247
+467% +$21.3K ﹤0.01% 6992
2021
Q2 		$5K Buy
+267
New +$3.66K ﹤0.01% 7378

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley's HOWL Position: Q2 2026 in Review

Morgan Stanley reduced its Werewolf Therapeutics (HOWL) stake by 43% in Q2 2026, selling an estimated $8.95K and leaving 19,108 shares worth $6.88K. The position accounts for ﹤0.01% of the portfolio, ranked #7143.

Morgan Stanley first reported a position in HOWL in Q2 2021 and has held it in 21 quarters since. The position peaked at $252K in Q3 2024. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Morgan Stanley held 19,108 shares of Werewolf Therapeutics worth $6.88K as of Q2 2026.
  • Morgan Stanley sold 14,691 Werewolf Therapeutics shares in Q2 2026, an estimated $8.95K.
  • Werewolf Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7143 holding.
  • Morgan Stanley first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Morgan Stanley's Werewolf Therapeutics position peaked at $252K in Q3 2024.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.